Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P25090
UPID:
FPR2_HUMAN
Alternative names:
FMLP-related receptor I; Formyl peptide receptor-like 1; HM63; Lipoxin A4 receptor; RFP
Alternative UPACC:
P25090; A8K3E2
Background:
N-formyl peptide receptor 2 (NPR2), also known as FMLP-related receptor I, Formyl peptide receptor-like 1, HM63, Lipoxin A4 receptor, and RFP, plays a pivotal role in immune response. It acts as a low affinity receptor for N-formyl-methionyl peptides, potent neutrophil chemotactic factors, triggering neutrophil activation via a G-protein that activates a phosphatidylinositol-calcium second messenger system. Furthermore, NPR2's interaction with the chemokine-like protein FAM19A5 stimulates macrophage chemotaxis and inhibits osteoclast differentiation, showcasing its anti-inflammatory potential by counteracting pro-inflammatory signals.
Therapeutic significance:
Understanding the role of N-formyl peptide receptor 2 could open doors to potential therapeutic strategies, particularly in modulating immune response and inflammation, offering insights into novel anti-inflammatory treatments.